| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 8256- | LCA, | Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice |
| - | in-vivo, | Colon, | CT26 |
| 8257- | LCA, | Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 8260- | LCA, | Licochalcone A Induces Ferroptosis in Hepatocellular Carcinoma via Reactive Oxygen Species Activated by the SLC7A11/GPX4 Pathway |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 8261- | LCA, | Licochalcone A induces T24 bladder cancer cell apoptosis by increasing intracellular calcium levels |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 8209- | LCA, | Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 8206- | LCA, | Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways |
| - | in-vivo, | GC, | BGC-823 |
| 8235- | LCA, | Anticancer effects of licochalcones: A review of the mechanisms |
| - | Review, | Var, | NA |
| 8214- | LCA, | Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade |
| - | vitro+vivo, | AML, | U937 |
| 8229- | LCA, | Licochalcone A: a review of its pharmacology activities and molecular mechanisms |
| - | Review, | Nor, | NA |
| 8210- | LCA, | Licochalcone A-Induced Human Bladder Cancer T24 Cells Apoptosis Triggered by Mitochondria Dysfunction and Endoplasmic Reticulum Stress |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8231- | LCA, | Maintenance of the Expression of c-FLIPL by Hsp70 to Resist Licochalcone A-Induced Anti-Colorectal Cancer Effect through ERK-Mediated Autophagy Induction |
| - | in-vitro, | CRC, | NA |
| 8222- | LCA, | Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways |
| - | in-vitro, | CCA, | KKU-100 | - | in-vitro, | CCA, | KKU-213 | - | in-vitro, | CCA, | KKU-214 | - | in-vitro, | CCA, | KKU-156 | - | in-vitro, | 0-Reserved, | KKU-452 |
| 8335- | LDN, | The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 8341- | LDN, | Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy |
| - | Review, | Var, | NA |
| 8338- | LDN, | Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway |
| - | vitro+vivo, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 8339- | LDN, | Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo |
| - | in-vivo, | Cerv, | HeLa |
| - | in-vitro, | Oral, | NA |
| 8288- | LE, | 18 β-glycyrrhetinic acid exhibits potent antitumor effects against colorectal cancer via inhibition of cell proliferation and migration |
| - | vitro+vivo, | CRC, | NA |
| 8269- | LE, | Glycyrrhiza glabra-Enhanced Extract and Adriamycin Antiproliferative Effect on PC-3 Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 8236- | LE, | Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects |
| - | Review, | Var, | NA |
| 8265- | LE, | Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response |
| - | vitro+vivo, | CRC, | NA |
| 8282- | LE, | Glycyrrhizic Acid Inhibits Proliferation of Gastric Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis |
| - | in-vitro, | GC, | MGC803 | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 |
| 8277- | LE, | Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights |
| - | Review, | Var, | NA |
| 8279- | LE, | 18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H460 |
| 2453- | LE, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 8130- | LF, | Lactoferrin targeting INTL1 receptor inhibits hepatocellular carcinoma progression via apoptosis and cell cycle signaling pathways |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8131- | LF, | Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma |
| - | in-vitro, | OS, | HSC2 | - | in-vitro, | OS, | HSC3 | - | in-vitro, | OS, | HSC4 | - | in-vitro, | Nor, | RT7 |
| 8143- | LF, | Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mTOR pathway to inhibit nasopharyngeal carcinoma metastasis |
| - | in-vitro, | NPC, | NA |
| 8196- | LGE, | Lemongrass essential oil and citral inhibit Src/Stat3 activity and suppress the proliferation/survival of small-cell lung cancer cells, alone or in combination with chemotherapeutic agents |
| - | in-vitro, | Lung, | NA |
| 8193- | LGE, | Targets and pathways involved in the antitumor activity of citral and its stereo-isomers |
| - | Review, | Var, | NA |
| 8191- | LGE, | Lemongrass (Cymbopogon citratus (D.C.) Stapf) Presents Antitumoral Effect and Improves Chemotherapy Activity in Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 8187- | LGE, | Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Ovarian, | SKOV3 |
| 8185- | LGE, | Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression |
| - | in-vitro, | Var, | NA |
| 8184- | LGE, | Cytotoxicity of citral against melanoma cells: The involvement of oxidative stress generation and cell growth protein reduction |
| - | in-vitro, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | HaCaT |
| 8292- | lign, | Anticancer potential of flaxseed lignans, their metabolites and synthetic counterparts in relation with molecular targets: current challenges and future perspectives |
| - | Review, | Var, | NA |
| 8298- | lign, | Inhibitory Effects of Enterolactone on Growth and Metastasis in Human Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8324- | LIN, | Linalool targets NR3C2 to inhibit NF-κB-mediated gastric cancer progression |
| - | vitro+vivo, | GC, | NA |
| 8327- | LIN, | Recent updates on bioactive properties of linalool |
| - | Review, | Var, | NA |
| 8325- | LIN, | Validating linalool as a potential drug for breast cancer treatment based on machine learning and molecular docking |
| - | in-vitro, | BC, | NA |
| 8317- | LIN, | Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways |
| - | in-vitro, | Liver, | HepG2 |
| 6464- | LIN, | 1,8-Cin, | Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Nor, | WI38 |
| 6479- | LIN, | Anticancer effect of linalool via cancer-specific hydroxyl radical generation in human colon cancer |
| - | in-vivo, | Colon, | HCT116 |
| 6481- | LIN, | Linalool inhibits 22Rv1 prostate cancer cell proliferation and induces apoptosis |
| - | in-vivo, | Pca, | 22Rv1 |
| 8375- | LT, | Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches |
| - | Review, | Var, | NA |
| 8395- | LT, | PacT, | Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma |
| - | in-vitro, | ESCC, | NA |
| 8370- | LT, | Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer |
| - | vitro+vivo, | Colon, | NA |
| 8384- | LT, | Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors |
| - | Review, | GC, | NA |
| 8386- | LT, | Luteolin induces apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia cell by regulating the PI3K/AKT signaling pathway |
| - | in-vitro, | ALL, | SUP-B15 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid